A Open-label, Randomized, Multicenter Study of the Safety, Tolerability, and Immunogenicity of GARDASIL Given Concomitantly with REPEVAX in Healthy Adolescents 11-17 Years of Age

Trial Profile

A Open-label, Randomized, Multicenter Study of the Safety, Tolerability, and Immunogenicity of GARDASIL Given Concomitantly with REPEVAX in Healthy Adolescents 11-17 Years of Age

Completed
Phase of Trial: Phase III

Latest Information Update: 18 Nov 2016

At a glance

  • Drugs Human papillomavirus vaccine recombinant quadrivalent Merck (Primary) ; DTaP poliovirus vaccine
  • Indications Cervical cancer; Cervical intraepithelial neoplasia; Diphtheria; Genital warts; Human papillomavirus infections; Pertussis; Poliomyelitis; Tetanus
  • Focus Adverse reactions; Pharmacodynamics; Registrational
  • Sponsors Merck & Co
  • Most Recent Events

    • 01 Apr 2010 Results published in Pediatric Infectious Disease Journal
    • 12 Jan 2010 Actual number of patients changed from 800 to 843 as reported by ClinicalTrials.gov.
    • 01 Oct 2008 Additional trial identifier (V501-024) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top